Shiina · 2015 · Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
Early study of cognitive tests in patients with schizophrenia
Would sprout extract intake change cognitive test results in patients with schizophrenia receiving usual drug treatment?
Human · open-label single-arm pilot trial
Key findings
Eight-week cognitive test results
In an open-label trial completed by seven patients with schizophrenia, accuracy on a card-learning task increased from baseline. Other cognitive tests and clinical symptoms showed no significant changes.
Study design
Ten outpatients were enrolled to take sprout extract tablets for eight weeks, and seven completed the study. The daily dose was based on 30mg of SFN-glucosinolate, or glucoraphanin; there was no comparison group.
- Participants
- Japan · 10 patients with schizophrenia
7 completed · before-and-after comparison - Intake and observation
- Glucoraphanin 30mg/day
8 weeks · added to usual treatment - Measures
- CogState cognitive tests · PANSS
Study context
An uncontrolled trial added glucoraphanin to usual treatment. Seven of 10 enrolled participants completed it.
Original paper and sources
An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.
- Journal
- Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2015 · 13(1): 62-67
- First published
- 2015-04-01